<DOC>
	<DOCNO>NCT01745198</DOCNO>
	<brief_summary>In retrospective analysis data 1100 patient , disease-delaying effect Cerefolin®/CerefolinNAC® examine term cognition . The purpose current study expand retrospective study dataset prospectively collect additional biomarker image data .</brief_summary>
	<brief_title>Effect Cerefolin®/CerefolinNAC® Biomarker Measurements</brief_title>
	<detailed_description>CerefolinNAC® orally administer prescription medical food , formulate combination L-methylfolate calcium ( Metafolin® ) , methylcobalamin , N-acetylcysteine . In retrospective analysis , disease-delaying effect Cerefolin®/CerefolinNAC® ( CFLN ) examine term cognition ( measure MCI Screen ( MCIS ) ) , functional capacity ( measure Functional Assessment Staging Test ( FAST ) ) . - treatment effect CFLN cognitive functional measure , biomarker measure patient Alzheimer 's disease relate disorder ( ADRD ) . The current study expand NAC-002b study dataset prospectively collect additional biomarker image data comprehensively assess , match sample patient . This allow precise evaluation cognitive functional outcome measure , biomarker measure assess attempt identify specific population condition CFLN effective . The sample consist patient homocysteinemia plus past/current CFLN treatment ( Treatment Group ) match without homocysteinemia plus past/current B12 , folate CFLN treatment ( Non-Treatment Group ) . Also 65 additional subject recruit non-Treatment group , use improve rate decline estimate cognitive functional outcome measure .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<criteria>With diagnosis normal aging ( NL ) , cognitive impairment dementia otherwise specify ( CI/D ) , ADRD With least one previous quantitative MRI ( qMRI ) With least one previous homocysteine level Without homocysteinemia plus past current B12 , folate Cerefolin® treatment , OR homocysteinemia plus past current Cerefolin® treatment Subjects meet inclusion criterion exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>homocysteinemia</keyword>
	<keyword>dementia</keyword>
	<keyword>depression</keyword>
	<keyword>vitamin B12</keyword>
	<keyword>folate</keyword>
	<keyword>mild cognitive impairment</keyword>
	<keyword>alzheimer 's</keyword>
	<keyword>homocysteine</keyword>
</DOC>